CP and chronic myelogenous leukemia, BCR-ABL1 positive: After imatinib and dasatinib, on March 2018, the FDA approved nilotinib (TASIGNA, Novartis Pharmaceuticals Corporation) for pediatric patients one year of age or older with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) [80].